Latest News and Press Releases

Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial...

Sequana Medical Obtains Convertible Financing of EUR 4.0 Million from Major Shareholders and Committed Share Subscription Facility of up to EUR 60 Million from GEM Continued support from major...

Transparency Notification from Shareholders Ghent, Belgium – 10 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid...

Transparency Notifications from Shareholders Ghent, Belgium – 3 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES FOLLOWING LOAN CONVERSIONS Conversion of EUR 0.53 million under the Sensinnovat 2020 loan, EUR 1.28 million under the 2024...

Transparency Notification from Shareholders Ghent, Belgium – 13 January 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid...

Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology alfapump® system is...

Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST Webinar to discuss US commercial roll-out following FDA...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis alfapump® is the first US approved active implantable medical device...

Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing Ghent, Belgium – 20 December 2024 – Sequana Medical NV (Euronext Brussels:...